Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

at or before the EASL meeting

and/or the Digestive Disease Week meeting. These meetings will take

place in April and May, respectively.

-- The company expects to initiate its 14-day triple combination study of

ITMN-191 in combination with Pegasys(R) and ribavirin, in the second

quarter of 2008. The study design and timeline will be shared at study

initiation.

-- An Investigational New Drug (IND) application is expected to be filed

by Roche for ITMN-191/R7227 in the second half of 2008 to gain FDA

approval to study the compound in the United States.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EST to discuss its financial results for the fourth quarter and full year 2007, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 32601453. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 32601453. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (I
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that it will ... May 7, 2015 after the close of the U.S. ... and webcast on Thursday, May 7, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:4/30/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... contract R&D services provider, today announced that its board ... dated April 29, 2015, from a consortium (the "Consortium") ... founder, chairman and chief executive officer of the Company, ... a transaction (the "Transaction") involving the acquisition of all ...
(Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Phytomer’s DOUCEUR ... sensitive and reactive skin while battling the weakening ... This restorative cream is formulated with star ingredient ... via biotechnology in a complex of soothing minerals ...
(Date:4/30/2015)... 2015 Clinovo Staffing Solutions ... Conference held in Orlando, FL on May 17-20th, ... with Leslie Kolman, Manager of Staffing Solutions, will present ... at Booth #17. , “We are excited to ... year”, Says Trisha Heredia, Senior Director of Staffing Solutions ...
Breaking Biology Technology:Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3
... 9 NuVasive, Inc. (Nasdaq:,NUVA), a medical device company ... the spine, announced today,that Kevin O,Boyle, Executive Vice President ... William Blair 28th Annual Growth Stock,Conference at the Four ... 8:30 a.m. CT., A live Web cast of ...
... ... Emphasizes Strategic Growth Plan and Capital Markets Interaction ... -, NEW ... a pharmaceutical,company dedicated to improving health through the development, manufacture,and commercialization of a broad range ...
... 9 ChanTest, the leading provider of ion,channel ... a completely redesigned Web site at http://www.ChanTest.com ... and CEO of ChanTest, the,company,s goal was to ... significant improvements in content, navigation, and visual,appeal. "The ...
Cached Biology Technology:NuVasive to Present at William Blair 28th Annual Growth Stock Conference 2NuVasive to Present at William Blair 28th Annual Growth Stock Conference 3American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 2American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 3ChanTest Launches Redesigned Web Site 2
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Edythe Broad Center of Regenerative Medicine and Stem Cell ... (blood-producing) stem cells from the bone marrow of patients ... study was led by Dr. Donald Kohn, professor of ... Sickle cell disease causes the body to ...
... wide range of problems from arthritis to cardiovascular disease, and ... problem. A new research report appearing in the July 2013 ... explain why DHA is important in reducing inflammation, and provides ... bring people back to optimal health. Specifically, researchers found that ...
... from cells of the embryonic nervous system. The ... range from spontaneous regression to fatal outcomes. Highly ... and overcoming the resistance mechanisms of highly aggressive ... effective treatments. Scientists from the department ...
Cached Biology News:UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials 2Harvard and USC scientists show how DHA resolves inflammation 2Neuroblastoma: Autophagy protects from chemotherapy 2